Review of GLP-1 molecular pharmacology covers receptor binding, signaling pathways, biased agonism, and how molecular understanding enables design of better GLP-1 drugs.
Key findingReview of GLP-1 molecular pharmacology covers receptor binding, signaling pathways, biased agonism,
What the researchers found
Review of GLP-1 molecular pharmacology covers receptor binding, signaling pathways, biased agonism, and how molecular understanding enables design of better GLP-1 drugs.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Review covers GLP-1 receptor signaling pathways, drug modification strategies, and their effects on metabolic outcomes.
How the study worked
In publication.
Who was studied
Review of molecular pharmacology — not a patient study
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.
Integrated pharmacy research & practice, 14, 59-72
Citation
Alzahrani, Abdullah M; Alshobragi, Ghada A; Alshehri, Abdullah M; Alzahrani, Majed S; Alshehri, Hasan A; Alzhrani, Rami M; Basudan, Samah; Alkatheeri, Ayed A; Almutairi, Salman A; Alzahrani, Yahya A. (2025). Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.. Integrated pharmacy research & practice, 14, 59-72. https://doi.org/10.2147/IPRP.S503501